The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid the growing focus on early neurodegenerative disease diagnostics, Abbott reportedly signed a licensing deal with ALZpath to use its pTau217 antibody for a blood-based Alzheimer's test on Alinity ci-series. Separately, the company declared its 410th consecutive quarterly dividend of $0.63 per share, underscoring financial stability and consistent shareholder returns.
The agreement arrives as the Alzheimer's blood-test market heats up, with peers like Roche developing similar assays. Per market data, ABT shares closed at $90.49 on June 24, 2026, trading in a range of $90.30–$92.92. The extended dividend streak reflects robust cash flows, even as Abbott ramps up diagnostic investments.
Sign in to access this content
Sign InLooking ahead, investors await regulatory approvals for the new test and commercial rollout. Technically, ABT trades near support at $90.30 and resistance at $92.92. Upcoming healthcare-sector catalysts and FDA decisions will be key drivers for the stock in coming months.